Correlation between serum interleukin 19 level and diabetic nephropathy

doi:10.3969/j.issn.1673-8640.2017.08.007

Abstract

Abstract:

Objective To investigate the correlation between serum interleukin 19（IL-19）level and diabetic nephropathy. Methods A total of 200 patients with type 2 diabetes mellitus（T2DM）were enrolled,and they were classified into non-albuminuria nephropathy group（102 cases）,micro-albuminuria nephropathy group（72 cases）and macro-albuminuria nephropathy group（26 cases）according to urinary albumin excretion（UAE）. A total of 50 healthy subjects were enrolled. Serum IL-19 level,high-sensitivity C-reactive protein（hs-CRP）,cystatin C（Cys C）,glycated hemoglobin A_1c（HbA_1c）and UAE were determined. Results Compared with healthy control group,serum IL-19 levels in micro-albuminuria nephropathy and macro-albuminuria nephropathy groups were higher（P<0.05）. Serum IL-19 level was positively correlated with hs-CRP, Cys C, UAE and HbA_1c（r=0.623, 0.611, 0.591 and 0.526,P<0.01）. Conclusions Serum IL-19 level is increased in patients with diabetic nephropathy. It might be involved in the development of diabetic nephropathy.

Key words: Interleukin 19, Diabetic nephropathy, Type 2 diabetes mellitus

CLC Number:

R446.62

LI Li, HU Juanyu, YU Zhengqing, MENG Hai. Correlation between serum interleukin 19 level and diabetic nephropathy[J]. Laboratory Medicine, 2017, 32(8): 691-694.

Figures/Tables 2

References 16

[1]	TABATA M,KADOMATSU T,FUKUHARA S,et al.Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance[J]. Cell Metab,2009,10(3):178-188.
[2]	FAGIANI E,CHRISTOFORI G.Angiopoietins in angiogenesis[J]. Cancer Lett,2013,328(1):18-26.
[3]	MATSUO Y,AZUMA Y T,KUWAMURA M,et al.Interleukin 19 reduces inflammation in chemically induced experimental colitis[J]. Int Immunopharmacol,2015,29(2):468-475.
[4]	BARRETT J C,CLAYTON D G,CONCANNON P,et al.Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes[J]. Nat Genet,2009,41(6):703-707.
[5]	DABHI B,MISTRY K N,PATEL H,et al.Vascular endothelial growth factor insertion/deletion gene polymorphism in West Indian patients of type 2 diabetes and diabetic nephropathy[J]. Indian J Biochem Biophys,2015,52(2):209-212.
[6]	BONOMINI M,PANDOLFI A.Chemerin in renal dysfunction and cardiovascular disease[J]. Vascul Pharmacol,2016,77:28-34.
[7]	MOON J Y,JEONG K H,LEE T W,et al.Aberrant recruitment and activation of T cells in diabetic nephropathy[J]. Am J Nephrol,2012,35(2):164-174.
[8]	FIELDING C A.Interleukin-19:a new target to aim for?[J]. Rheumatology(Oxford),2012,51(3):399-400.
[9]	SABAT R,WALLACE E,ENDESFELDER S,et al.IL-19 and IL-20:two novel cytokines with importance in inflammatory diseases[J]. Expert Opin Ther Targets,2007,11(5):601-612.
[10]	CUNEO A A,HERRICK D,AUTIERI M V.IL-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability[J]. J Mol Cell Cardiol,2010,49(4):647-654.
[11]	SAVASAN Z A,CHAIWORAPONGSA T,ROMERO R,et al.Interleukin-19 in fetal systemic inflammation[J]. J Matern Fetal Neonatal Med,2012,25(7):995-1005.
[12]	GABUNIA K,AUTIERI M V.Interleukin 19 can enhance angiogenesis by macrophage polarization[J]. Macrophage(Houst),2015,2(1):e562.
[13]	JENNINGS P,CREAN D,ASCHAUER L,et al.Interleukin-19 as a translational indicator of renal injury[J]. Arch Toxicol,2015,89(1):101-106.
[14]	JAIN S,GABUNIA K,KELEMEN S E,et al.The anti-inflammatory cytokine interleukin 19 is expressed by and angiogenic for human endothelial cells[J]. Arterioscler Thromb Vasc Biol,2011,31(1):167-175.
[15]	American Diabetes Association.Standards of medical care in diabetes-2010[J]. Diabetes Care,2010,33(Suppl 1):S11-S61.
[16]	李卿,居漪,金中淦,等. 糖化血红蛋白IFCC参考方法及实验室网络比对[J]. 检验医学,2016,31(7):607-609.

组别	例数（男/女）	IL-19 （pg/mL）	hs-CRP （mg/L）	Cys C (mg/L)	UAE （mg/24 h）	HbA_1c （%）
T2DM组	200（109/91）	40.5±12.0^*	3.6±1.5	1.7±0.7	140±120^*	8.5±1.8
无蛋白尿组	102 （55/47）	35.8±12.3^*#	3.0±0.9	1.3±0.5	18±14	8.3±1.5
微量蛋白尿肾病组	72（39/33）	49.4±13.6^*#	4.3±1.2	2.1±1.0	180±130^*	8.7±2.0
大量蛋白尿肾病组	26（15/11）	61.3±18.2^*	5.6±1.0	3.9±1.1	510±225^*	8.6±1.8
对照组	50（30/20）	16.2±8.5	0.7±0.3	0.6±0.2	7±2	5.4±0.5

组别	例数（男/女）	IL-19 （pg/mL）	hs-CRP （mg/L）	Cys C (mg/L)	UAE （mg/24 h）	HbA_1c （%）
T2DM组	200（109/91）	40.5±12.0^*	3.6±1.5	1.7±0.7	140±120^*	8.5±1.8
无蛋白尿组	102 （55/47）	35.8±12.3^*#	3.0±0.9	1.3±0.5	18±14	8.3±1.5
微量蛋白尿肾病组	72（39/33）	49.4±13.6^*#	4.3±1.2	2.1±1.0	180±130^*	8.7±2.0
大量蛋白尿肾病组	26（15/11）	61.3±18.2^*	5.6±1.0	3.9±1.1	510±225^*	8.6±1.8
对照组	50（30/20）	16.2±8.5	0.7±0.3	0.6±0.2	7±2	5.4±0.5